Changes in the brain and plasma Aβ peptide levels with age and its relationship with cognitive impairment in the APPswe/PS1dE9 mouse model of Alzheimer's disease

Neuroscience

Volumn 263, Issue , 2014, Pages 269-279

  Izco, M ^a   Martinez P ^b   Corrales, A ^b   Fandos, N ^a   Garcia S ^b   Insua, D ^a   Montanes M ^a   Perez Grijalba V ^a   Rueda, N ^b   Vidal, V ^b   Martinez Cue C ^b   Pesini, P ^a   Sarasa, M ^a  

^a Araclon Biotech   (Spain)

^b UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

amyloid peptides; Alzheimer's disease; APPswe PS1dE9 transgenic animal model; Brain A levels; Memory deficits; Plasma A levels

Indexed keywords

ALZHEIMER'S DISEASE; APPSWE/PS1DE9 TRANSGENIC ANIMAL MODEL; BRAIN AΒ LEVELS; MEMORY DEFICITS; PLASMA AΒ LEVELS; Β-AMYLOID PEPTIDES;

AGE FACTORS; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; MALE; MAZE LEARNING; MEMORY DISORDERS; MICE; MICE, TRANSGENIC; PRESENILIN-1;

EID: 84894037078     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2014.01.003     Document Type: Article

References (65)

1. Andra K., Abramowski D., Duke M., Probst A., Wiederhold K.H., Burki K., Goedert M., Sommer B., Staufenbiel M. Expression of APP in transgenic mice: a comparison of neuron-specific promoters. Neurobiol Aging 1996, 17:183-190.
2. Aso E., Lomoio S., López-González I., Joda L., Carmona M., Fernández-Yagüe N., Moreno J., Juvés S., Pujol A., Pamplona R., Portero-Otin M., Martín V., Díaz M., Ferrer I. Amyloid generation and dysfunctional immunoproteasome activation with disease progression in animal model of familial Alzheimer's disease. Brain Pathol 2012, 22:636-653.
3. Banks W.A., Robinson S.M., Verma S., Morley J.E. Efflux of human and mouse amyloid beta proteins 1-40 and 1-42 from brain: impairment in a mouse model of Alzheimer's disease. Neuroscience 2003, 121:487-492.
4. Burdick D., Soreghan B., Kwon M., Kosmoski J., Knauer M., Henschen A., Yates J., Cotman C., Glabe C. Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. J Biol Chem 1992, 267:546-554.
5. Campion D., Flaman J.M., Brice A., Hannequin D., Dubois B., Martin C., Moreau V., Charbonnier F., Didierjean O., Tardieu S. Mutations of the presenilin I gene in families with early-onset Alzheimer's disease. Hum Mol Genet 1995, 4:2373-2377.
6. Cao D., Lu H., Lewis T.L., Li L. Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. J Biol Chem 2007, 282:36275-36282.
7. Chen G., Chen K.S., Knox J., Inglis J., Bernard A., Martin S.J., Justice A., McConlogue L., Games D., Freedman S.B., Morris R.G. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 2000, 408:975-979.
8. Davson H., Segal M.B. The return of the cerebrospinal fluid to the blood: the drainage mechanism. Physiology of the CSF and blood-brain barriers 1996, 489-523. CRC Press, Boca Raton. H. Davson, M.B. Segal (Eds.).
9. Deane R., Wu Z., Zlokovic B.V. RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 2004, 35:2628-2631.
10. DeMattos R.B., Bales K.R., Cummins D.J., Paul S.M., Holtzman D.M. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 2002, 295:2264-2267.
11. Devanand D.P., Pradhaban G., Liu X., Khandji A., De Santi S., Segal S., Rusinek H., Pelton G.H., Honig L.S., Mayeux R., Stern Y., Tabert M.H., de Leon M.J. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology 2007, 68(11):828-836.
12. Dodart J.C., Mathis C., Bales K.R., Paul S.M., Ungerer A. Behavioral deficits in APP(V717F) transgenic mice deficient for the apolipoprotein E gene. Neuroreport 2000, 11:603-607.
13. Filali M., Lalonde R. Age-related cognitive decline and nesting behavior in an APPswe/PS1 bigenic model of Alzheimer's disease. Brain Res 2009, 1292:93-99.
14. Franklin K.B.J., Paxinos G. The mouse brain in stereotaxic coordinates 1997, Academic Press. Inc., San Diego, CA.
15. Gallo M., Marcello N., Curcio S.A., Colao R., Geracitano S., Bernardi L., Anfossi M., Puccio G., Frangipane F., Clodomiro A., Mirabelli M., Vasso F., Smirne N., Muraca G., Di L.R., Maletta R., Ghidoni E., Bugiani O., Tagliavini F., Giaccone G., Bruni A.C. A novel pathogenic PSEN1 mutation in a family with Alzheimer's disease: phenotypical and neuropathological features. J Alzheimers Dis 2011, 25:425-431.
16. Garcia-Alloza M., Robbins E.M., Zhang-Nunes S.X., Purcell S.M., Betensky R.A., Raju S., Prada C., Greenberg S.M., Bacskai B.J., Frosch M.P. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis 2006, 24:516-524.
17. Goate A., Chartier-Harlin M.C., Mullan M., Brown J., Crawford F., Fidani L., Giuffra L., Haynes A., Irving N., James L. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991, 349:704-706.
18. Gravina S.A., Ho L., Eckman C.B., Long K.E., Otvos L., Younkin L.H., Suzuki N., Younkin S.G. Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J Biol Chem 1995, 270:7013-7016.
19. Henneman W.J., Sluimer J.D., Barnes J., van der Flier W.M., Sluimer I.C., Fox N.C., Scheltens P., Vrenken H., Barkhof F. Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. Neurology 2009, 72(11):999-1007.
20. Herreman A., Hartmann D., Annaert W., Saftig P., Craessaerts K., Serneels L., Umans L., Schrijvers V., Checler F., Vanderstichele H., Baekelandt V., Dressel R., Cupers P., Huylebroeck D., Zwijsen A., Van L.F., De S.B. Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc Natl Acad Sci U S A 1999, 96:11872-11877.
21. Holcomb L., Gordon M.N., McGowan E., Yu X., Benkovic S., Jantzen P., Wright K., Saad I., Mueller R., Morgan D., Sanders S., Zehr C., O'Campo K., Hardy J., Prada C.M., Eckman C., Younkin S., Hsiao K., Duff K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 1998, 4:97-100.
22. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
23. Insua D., Suarez M.-L., Santamarina G., Sarasa M., Pesini P. Dogs with canine counterpart of Alzheimer's disease lose noradrenergic neurons. Neurobiol Aging 2010, 31:625-635.
24. Izco M., Pesini P., Pérez-Grijalba V., Fandos N., Sarasa M. Optimized protocol for amyloid-β extraction from the brain. J Alzheimer's Dis 2013, 34:835-839.
25. Jankowsky J.L., Fadale D.J., Anderson J., Xu G.M., Gonzales V., Jenkins N.A., Copeland N.G., Lee M.K., Younkin L.H., Wagner S.L., Younkin S.G., Borchelt D.R. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 2004, 13:159-170.
26. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., St George-Hyslop P., Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408:979-982.
27. Kawarabayashi T., Younkin L.H., Saido T.C., Shoji M., Ashe K.H., Younkin S.G. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 2001, 21:372-381.
28. Keller L., Welander H., Chiang H.H., Tjernberg L.O., Nennesmo I., Wallin A.K., Graff C. The PSEN1 I143T mutation in a Swedish family with Alzheimer's disease: clinical report and quantification of Abeta in different brain regions. Eur J Hum Genet 2010, 18:1202-1208.
29. Kuo Y.M., Crawford F., Mullan M., Kokjohn T.A., Emmerling M.R., Weller R.O., Roher A.E. Elevated A beta and apolipoprotein E in A betaPP transgenic mice and its relationship to amyloid accumulation in Alzheimer's disease. Mol Med 2000, 6:430-439.
30. Kuo Y.M., Beach T.G., Sue L.I., Scott S., Layne K.J., Kokjohn T.A., Kalback W.M., Luehrs D.C., Vishnivetskaya T.A., Abramowski D., Sturchler-Pierrat C., Staufenbiel M., Weller R.O., Roher A.E. The evolution of A beta peptide burden in the APP23 transgenic mice: implications for A beta deposition in Alzheimer disease. Mol Med 2001, 7:609-618.
31. Lalonde R., Kim H.D., Maxwell J.A., Fukuchi K. Exploratory activity and spatial learning in 12-month-old APP(695)SWE/co+PS1/DeltaE9 mice with amyloid plaques. Neurosci Lett 2005, 390:87-92.
32. Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., Ashe K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440:352-357.
33. Lleo A., Berezovska O., Growdon J.H., Hyman B.T. Clinical, pathological, and biochemical spectrum of Alzheimer disease associated with PS-1 mutations. Am J Geriatr Psychiatry 2004, 12:146-156.
34. Locascio J.J., Growdon J.H., Corkin S. Cognitive test performance in detecting, staging, and tracking Alzheimer's disease. Arch Neurol 1995, 52:1087-1099.
35. Lui J.K., Laws S.M., Li Q., Villemagne V.L., Ames D., Brown B., Bush A.I., Ruyck K.D., Dromey J., Ellis K.A., Faux N.G., Foster J., Fowler C., Gupta V., Hudson P., Laughton K., Masters C.L., Pertile K., Rembach A., Rimajova M., Rodrigues M., Rowe C.C., Rumble R., Szoeke C., Taddei K., Martins R.N., Trounson B., Ward V., Martins R.N. Plasma Amyloid-β as a biomarker in Alzheimer's Disease: the AIBL study of aging. J Alzheimer's Dis 2010, 20:1233-1242.
36. Manaye K.F., Wang P.C., O'Neil J.N., Huang S.Y., Xu T., Lei D.L., Tizabi Y., Ottinger M.A., Ingram D.K., Mouton P.R. Neuropathological quantification of dtg APP/PS1: neuroimaging, stereology, and biochemistry. Age (Dordr) 2007, 29:87-96.
37. Mehta N.D., Refolo L.M., Eckman C., Sanders S., Yager D., Perez-Tur J., Younkin S., Duff K., Hardy J., Hutton M. Increased Abeta 42(43) from cell lines expressing presenilin 1 mutations. Ann Neurol 1998, 43:256-258.
38. Minkeviciene R., Ihalainen J., Malm T., Matilainen O., Keksa-Goldsteine V., Goldsteins G., Iivonen H., Leguit N., Glennon J., Koistinaho J., Banerjee P., Tanila H. Age-related decrease in stimulated glutamate release and vesicular glutamate transporters in APP/PS1 transgenic and wild-type mice. J Neurochem 2008, 105:584-594.
39. Montañés M., Casabona D., Sarasa L., Pesini P., Sarasa M. Prevention of amyloid-β fibril formation using antibodies against the C-terminal region of amyloid-β1-40 and amyloid-β1-42. J Alzheimer's Dis 2013, 34:133-137.
40. Nakazawa K., Sun L.D., Quirk M.C., Rondi-Reig L., Wilson M.A., Tonegawa S. Hippocampal CA3 NMDA receptors are crucial for memory acquisition of one-time experience. Neuron 2003, 38:305-315.
41. Oksman M., Iivonen H., Hogyes E., Amtul Z., Penke B., Leenders I., Broersen L., Lutjohann D., Hartmann T., Tanila H. Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol Dis 2006, 23:563-572.
42. Pesini P., Perez-Grijalba V., Monleon I., Boada M., Tarraga L., Martinez-Lage P., San-Jose I., Sarasa M. Reliable measurements of the beta-amyloid pool in blood could help in the early diagnosis of AD. Int J Alzheimers Dis 2012, 2012:604141.
43. Pham E., Crews L., Ubhi K., Hansen L., Adame A., Cartier A., Salmon D., Galasko D., Michael S., Savas J.N., Yates J.R., Glabe C., Masliah E. Progressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins. FEBS J 2010, 277:3051-3067.
44. Raber J., Wong D., Buttini M., Orth M., Bellosta S., Pitas R.E., Mahley R.W., Mucke L. Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. Proc Natl Acad Sci U S A 1998, 95:10914-10919.
45. Richards J.G., Higgins G.A., Ouagazzal A.M., Ozmen L., Kew J.N., Bohrmann B., Malherbe P., Brockhaus M., Loetscher H., Czech C., Huber G., Bluethmann H., Jacobsen H., Kemp J.A. PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation. J Neurosci 2003, 23:8989-9003.
46. Rogaev E.I., Sherrington R., Rogaeva E.A., Levesque G., Ikeda M., Liang Y., Chi H., Lin C., Holman K., Tsuda T. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995, 376:775-778.
47. Ruan L., Kang Z., Pei G., Le Y. Amyloid deposition and inflammation in APPswe/PS1dE9 mouse model of Alzheimer's disease. Curr Alzheimer Res 2009, 6:531-540.
48. Saab B.J., Saab A.M., Roder J.C. Statistical and theoretical considerations for the platform re-location water maze. J Neurosci Methods 2011, 198:44-52.
49. Savonenko A.V., Xu G.M., Price D.L., Borchelt D.R., Markowska A.L. Normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant APP SWE. Neurobiol Dis 2003, 12:194-211.
50. Savonenko A., Xu G.M., Melnikova T., Morton J.L., Gonzales V., Wong M.P., Price D.L., Tang F., Markowska A.L., Borchelt D.R. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis 2005, 18:602-617.
51. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001, 81:741-766.
52. Selkoe D.J. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 2008, 192:106-113.
53. Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., Regan C.M., Walsh D.M., Sabatini B.L., Selkoe D.J. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008, 14:837-842.
54. Shibata M., Yamada S., Kumar S.R., Calero M., Bading J., Frangione B., Holtzman D.M., Miller C.A., Strickland D.K., Ghiso J., Zlokovic B.V. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000, 106:1489-1499.
55. Small B.J., Mobly J.L., Laukka E.J., Jones S., Backman L. Cognitive deficits in preclinical Alzheimer's disease. Acta Neurol Scand Suppl 2003, 179:29-33.
56. Steele R.J., Morris R.G. Delay-dependent impairment of a matching-to-place task with chronic and intrahippocampal infusion of the NMDA-antagonist D-AP5. Hippocampus 1999, 9:118-136.
57. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., Rothacher S., Ledermann B., Burki K., Frey P., Paganetti P.A., Waridel C., Calhoun M.E., Jucker M., Probst A., Staufenbiel M., Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A 1997, 94:13287-13292.
58. Timmer N.M., Van D.L., Van der Zee C.E., Kiliaan A., De Waal R.M., Verbeek M.M. Enoxaparin treatment administered at both early and late stages of amyloid beta deposition improves cognition of APPswe/PS1dE9 mice with differential effects on brain Abeta levels. Neurobiol Dis 2010, 40:340-347.
59. Toledo J.B., Vanderstichele H., Figurski M., Aisen P.S., Petersen R.C., Weiner M.W., Jack C.R., Jaqust W., Decarli C., Toga A.W., Toledo E., Xie S.X., Lee V.M., Trojanowski J.Q., Shaw L.M. Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol 2011, 122:401-413.
60. Vogelgesang S., Cascorbi I., Schroeder E., Pahnke J., Kroemer H.K., Siegmund W., Kunert-Keil C., Walker L.C., Warzok R.W. Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 2002, 12:535-541.
61. Welsh K., Butters N., Hughes J., Mohs R., Heyman A. Detection of abnormal memory decline in mild cases of Alzheimer's disease using CERAD neuropsychological measures. Arch Neurol 1991, 48:278-281.
62. Xiong H., Callaghan D., Wodzinska J., Xu J., Premyslova M., Liu Q.Y., Connelly J., Zhang W. Biochemical and behavioral characterization of the double transgenic mouse model (APPswe/PS1dE9) of Alzheimer's disease. Neurosci Bull 2011, 27:221-232.
63. Yan P., Bero A.W., Cirrito J.R., Xiao Q., Hu X., Wang Y., Gonzales E., Holtzman D.M., Lee J.M. Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci 2009, 29:10706-10714.
64. Zeng H., Chattarji S., Barbarosie M., Rondi-Reig L., Philpot B.D., Miyakawa T., Bear M.F., Tonegawa S. Forebrain-specific calcineurin knockout selectively impairs bidirectional synaptic plasticity and working/episodic-like memory. Cell 2001, 107:617-629.
65. Zhang W., Bai M., Xi Y., Hao J., Liu L., Mao N., Su C., Miao J., Li Z. Early memory deficits precede plaque deposition in APPswe/PS1dE9 mice: Involvement of oxidative stress and cholinergic dysfunction. Free Radic Biol Med 2012, 52:1443-1452.